Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion

Vaccine

Volumn 28, Issue 19, 2010, Pages 3428-3434

  Fowler, V L ^a   Knowles, N J ^a   Paton, D J ^a   Barnett, P V ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

Foot and mouth disease; Marker vaccine; VP1 G H loop

Indexed keywords

ADJUVANT; FOOT AND MOUTH DISEASE VACCINE; INACTIVATED VACCINE; MARKER VACCINE; PROTEIN VP1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CATTLE; CONTROLLED STUDY; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GENE DELETION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; SERUM; VACCINATION; VIRUS INACTIVATION; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CATTLE; CATTLE DISEASES; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; NEUTRALIZATION TESTS; OILS; SEQUENCE DELETION; VACCINES, INACTIVATED; VACCINES, MARKER; VIRAL VACCINES;

EID: 77950520134     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.074     Document Type: Article

References (31)

1. Doel T.R. Vaccines FMD. Virus Res 91 (2003) 81-99
2. Mackay D.K., Forsyth M.A., Davies P.R., and Salt J.S. Antibody to the non-structural proteins of foot-and-mouth disease virus in vaccinated animals exposed to infection. Vet Q 20 (1998) S9-S11 [supplement]
3. Sorensen K.J., Madsen K.G., Madsen E.S., Salt J.S., Nqindi J., and Mackay D.K.J. Differentiation of infection from vaccination in foot-and-mouth disease by the detection of antibodies to the non-structural proteins 3D 3AB and 3ABC in ELISA using antigens expressed in baculovirus. Arch Virol 143 (1998) 1461-1476
4. Fox G., Parry N.R., Barnett P.V., McGinn B., Rowlands D.J., and Brown F. The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol 70 (1989) 625-637
5. Taboga O., Tami C., Carrillo E., Nunez J.I., Rodriguez A., Saiz J.C., et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol 71 (1997) 2606-2614
6. Rieder E., Baxt B., Lubroth J., and Mason P. Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralising antibodies and protective immunity to multiple serotypes of FMDV. J Virol 68 (1994) 7092-7098
7. Bergmann I.E., Tiraboschi B., Mazzuca G., Fernandez E., Michailoff C.A., Scodeller E.A., et al. Serological and biochemical analysis of foot-and-mouth disease virus (serotype C3) isolated in Argentina between 1981 and 1986. Vaccine 6 (1988) 245-252
8. Mateu M.G., Camarero J.A., Giralt E., Andreu D., and Domingo E. Direct evaluation of the immunodominance of a major antigenic site of foot-and-mouth disease in a natural host. Virology 206 (1995) 298-306
9. Thomas A.A.M., Woortmeijer R.J., Puijk W., Barteling S.J., and Meloen R.H. Antigenic sites of foot-and-mouth disease virus type A10. J Virol 62 (1988) 2782-2789
10. Aggarwal N., and Barnett P.V. Antigenic sites of foot-and-mouth disease virus (FMDV): an analysis of the specificities of anti-FMDV antibodies after vaccination of susceptible host species. J Gen Virol 83 (2002) 775-782
11. Barnett P.V., Samuel A.R., Pullen L., Ansell D., Butcher R.N., and Parkhouse R.M. Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognise similar antigenic features to those defined by the mouse. J Gen Virol 79 (1998) 1687-1697
12. McCullough K.C., Crowther J.R., Butcher R.N., Carpenter W.C., Brocchi E., Capucci L., et al. Immune protection against foot-and-mouth disease virus studied using virus-neutralising and non-neutralising concentrations of monoclonal antibodies. Immunology 58 (1986) 421-428
13. Frimann T.H., Barfoed A.M., Aasted B., and Kamstrup S. Vaccination of mice with plasmids expressing processed capsid protein of foot-and-mouth disease virus-importance of dominant and subdominant epitopes for antigenicity and protection. Vaccine 25 (2007) 6191-6200
14. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41 (1999) 95-98
15. Rweyemamu M. Antigenic variation in foot-and-mouth disease: studies based on the virus neutralisation reaction. J Biol Stand 12 (1984) 323-337
16. Bolwell C., Clarke B.E., Parry N.R., Ouldridge E.J., Brown F., and Rowlands D.J. Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies. J Gen Virol 70 (1989) 59-68
17. 61 alone and complexed with oligosaccharide receptor: receptor conservation in the face of antigenic variation. J Gen Virol 86 (2005) 1909-1920
18. Logan D., Abu-Ghazaleh R., Blakemore W., Curry S., Jackson T., King A., et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 362 (1993) 566-568
19. Lambert C., Leonard N., De Bolle X., and Depiereux E. ESyPred3D: prediction of proteins 3D structures. Bioinformatics 18 (2002) 1250-1256
20. Sayle R.A., and Milner-White E.J. RASMOL: biomolecular graphics for all. Trends Biochem Sci 20 (1995) 374
21. Brehm K.E., Kumar N., Thlke H.-H., and Haas B. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. Vaccine 26 (2008) 1681-1687
22. Fowler V., Paton D.J., Rieder E., and Barnett P.V. Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle. Vaccine 26 (2008) 1982-1989
23. Van Oirschot J.T., Kaashoek M.J., Rijsewijk F.A., and Stegeman J.A. The use of marker vaccines in eradication of herpesviruses. J Biotech 44 (1996) 75-81
24. Van Gennip H.G., Bouma A., van Rijn P.A., Widjojoatmodjo M.N., and Moormann R. Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV. Vaccine 20 (2002) 1544-1556
25. Widjojoatmodjo M.N., van Gennip H.G., Bouma A., van Rijn P.A., and Moormann R.J. Classical swine fever virus E(rns) deletion mutants: trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines. J Virol 74 (2000) 2973-2980
26. Mebatsion T., Koolen M.J., de Vaan L.T., de Haas N., Braber M., Romer-Oberdorfer A., et al. Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. J Virol 76 (2002) 10138-10146
27. Peeters B.P., de Leeuw O.S., Verstegen I., Koch G., and Gielkens A.L. Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine 19 (2001) 1616-1627
28. Castillo-Olivares J., Wieringa R., Bakonyi T., de Vries A.A.F., Davis-Poynter N.J., and Rottier P.J.M. Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain. J Virol 15 (2003) 8470-8480
29. Barnett P.V., Statham R.J., Vosloo W., and Haydon D.T. Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach. Vaccine 21 (2003) 3240-3248
30. Paton D.J., Valarcher J.-F., Bergmann I., Matlho O.G., Zakharov V.M., Palma E.L., et al. Selection of foot-and-mouth disease vaccine strains-a review. Rev Sci Tech 24 (2005) 981-993
31. Li Y., Stirling C.M.A., Denyer M.S., Hamblin P., Hutchings G., Takamatsu H.-H., et al. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost. Vaccine 21 (2008) 2647-2656